Kornimate/medical-research-clean huggingface dataset:
acridine carboxamide in treating patients with recurrent glioblastoma multiforme

Conditions: Brain and Central Nervous System Tumors

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of acridine carboxamide in treating patients who have recurrent glioblastoma multiforme.

objectives: i. determine the efficacy acridine carboxzmide in terms of objective response rate and response duration in patients with glioblastoma multiforme. ii. determine the toxicities of this treatment regimen in this patient population. outline: this is a multicenter study. patients receive acridine carboxamide iv continuously over days 1-5. treatment repeats every 3 weeks for at least 2 courses and up to a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. patients are followed every 6 weeks until disease progression. projected accrual: a total of 14-25 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically or cytologically confirmed recurrent glioblastoma multiforme measurable disease on contrast mri lesion at least 2 cm in diameter patient characteristics: age: 18 and over performance status: ecog 0-2 karnofsky 70-100% life expectancy: at least 3 months hematopoietic: wbc greater than 3,000/mm3 platelet count greater than 100,000/mm3 hepatic: bilirubin less than 1.5 times upper limit of normal (uln) alkaline phosphatase no greater than 2 times uln transaminases no greater than 2 times uln renal: creatinine no greater than 1.5 mg/dl cardiovascular: normal cardiac function no ischemic heart disease within the past 6 months normal electrocardiogram other: no unstable systemic diseases no active uncontrolled infections no prior or other concurrent malignancies except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix no psychological, familial, sociological, or geographical condition that would preclude study not pregnant or nursing fertile patients must use effective contraception prior concurrent therapy: biologic therapy: not specified chemotherapy: at least 6 weeks since prior adjuvant chemotherapy for brain tumor no other prior chemotherapy endocrine therapy: must be on stable or decreasing doses of corticosteroids for at least 2 weeks radiotherapy: at least 3 months since prior radiotherapy to the brain no prior high dose radiotherapy no prior stereotactic boost or implant radiotherapy surgery: no prior surgery (except biopsy) for recurrent brain tumor at least 3 months since prior surgery for primary brain tumor other: no other concurrent anticancer agents no other concurrent investigational therapy

Keywords: recurrent adult brain tumor adult glioblastoma adult giant cell glioblastoma adult gliosarcoma
outcomes of transanal tran-section and single-stapled (ttss) ileal pouch-anal anastomosis

Conditions: Ulcerative Colitis

Summary: this study aims to compare the functional and surgical outcomes of ulcerative colitis (uc) patients undergoing transanal transection and singl-stapled (ttss) versus double-stapled ileal pouch-anal anastomosis (ipaa)

ileal pouch-anal anastomosis (ipaai in ulcerative colitis (uc) patients is usually performed by double-stapling technique after rectal transection with a linear stapler. double-stapling is increasingly criticized for the uneven longer cuffs and potential weak points. the transanal transection and single-stapled (ttss) approach may potentially overcome the limitations of double-stapling. a single-stapled anastomosis may be accomplished through a transanal rectal transection followed by bottom-up dissection (transanal-ileal pouch-anal anastomosis) or through an abdominal, rectal dissection and subsequent transanal transection and single-stapled anastomosis. ttss-ipaa approach was shown to provide reduced rectal cuff length and reduced rate of urgency at six months after stoma closure. however, the retrospective and single-center features of these findings may prevent a robust conclusion about the superiority of ttss-ipaa. the purpose of this study is to compare short-term and functional outcomes of double-stapling versus ttss techniques for ipaa in uc patients in a prospective multicentric cohort study.

Eligibility criteria:
inclusion criteria: * adult (≥ 18 years old) patients diagnosed with drug-refractory and/or steroid-dependent uc scheduled for elective restorative proctectomy. * patients scheduled for robotic or laparoscopic surgery exclusion criteria: * planned open surgery. * concomitant colorectal cancer or dysplasia. patients with an incidental intraoperative diagnosis of colorectal cancer will be withdrawn from the study.

Keywords: ileal pouch-anal anastomosis intestinal function
prospect - profiling of resistance patterns & oncogenic signaling pathways in evaluation of cancers of the thorax and therapeutic target identification

Conditions: Lung Cancer; Cancer of Thorax

Summary: in this project, we will use therapeutic target -focused (ttf) profiling, genome-wide mrna profiling and assessments of tumor phosphopeptides and dna that are shed into the blood stream to define how various molecular factors alone and in combination relate to resistance to therapy, to prognosis, and to metastatic patterns at relapse. we will examine how the presence of factors that drive cell growth, antagonize apoptosis, or confer resistance in other ways may counter the effect of systemic therapies and/or promote rapid tumor recurrence. in this way, we will identify new, previously unappreciated potential therapeutic targets while also identifying which targets are most likely to increase resistance to therapy and worsen prognosis.

objectives: 1. to develop a therapeutic target -focused (ttf) profiling platform and to use it in vitro to identify potential therapeutic targets associated with therapeutic resistance and to develop novel approaches against these potential targets. 2. to use tumor tissue ttf profiling along with genome wide mrna profiling, serum phosphopeptide profiling and plasma dna profiling to identify and evaluate molecular targets and pathways that contribute to therapeutic sensitivity or resistance, prognosis, and recurrence patterns in patients with operable non-small cell lung carcinoma (nsclc).

Eligibility criteria:
inclusion criteria: eligible patients should be ones who have stage i-iiia non-small cell lung cancer (nsclc) and undergo surgical resection with or without neoadjuvant chemotherapy as part of standard treatment, and have a information of demographics, smoking history, preoperative clinical data, and follow -up data including adjuvant therapy, relapse, and treatment at relapse. we will include the three major nsclc histologic subtypes, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma - exclusion criteria: none
diet, genes and colorectal cancer - with focus on toll-like receptor polymorphisms

Conditions: Colorectal Cancer

Summary: the aim of this study is to investigate the interaction between diet - primary meat and fiber - and polymorphisms in toll-like receptors in relation to risk of colorectal cancer in a danish prospective cohort.

meat and dietary fibers have been associated with increased and decreased risk of colorectal cancer (crc), respectively. toll-like receptors (tlrs) regulate intestinal immune response in a complex interplay between the mucosal epithelium and the microbiota and may therefore be important modulators of diet-induced crc and interact with other inflammatory mediators. the aim of the study is to investigate the association with functional tlr polymorphisms in relation to risk of crc and their interaction with dietary factors. additionally, interactions with previously studied polymorphisms in il10, il1b, ptgs2 and nfkb1 will be assessed in order to examine possible biological pathways in meat-induced crc. data are retrieved from the danish prospective "diet, cancer and health" study encompassing 57,053 persons which were recruited between 1993 to 1997. between 1994 and 31th december 2009, 1038 crc cases has been diagnosed. a sub-cohort of 1857 persons has been randomly selected within the full cohort at time of entry into the cohort. the study design is a nested case-cohort study.

Eligibility criteria:
inclusion criteria: * born in denmark and had no previous cancers at study entry exclusion criteria: * previous or present cancer(s) at study entry

Keywords: gene-environment interaction candidate gene western style diet toll-like receptors prospective study nested case-cohort
dose-attenuated ist and hetrombopag in elderly (≥65 years) patients with severe aplastic anemia

Conditions: Sever Aplastic Anaemia; Elderly (People Aged 65 or More); Immunosuppressive Treatment

Summary: this is a prospetive,single-center, single-arm, phase iib clinical study.this study aims to evaluate the efficacy and safety of dose-attenuated ist combined with hetrombopag in elderly patients (≥65 years) with vsaa/saa.

design : prospective, single-center, single-arm, open-label phase iib trial. intervention : p-atg : 15 mg/kg/day iv ×5 days. cyclosporine : 3 mg/kg/day (adjusted to trough 100-200 μg/l). hetrombopag : 15 mg daily. follow-up : weekly for 24 weeks, with bone marrow evaluation at 24 weeks. inclusion criteria : confirmed diagnosis of vsaa/saa. age ≥65 years. completion of all screening assessments. ability to swallow oral medication. signed informed consent (by patient or legal guardian if patient is incapacitated). exclusion criteria : clonal cytogenetic abnormalities (excluding isolated -y or +8). prior treatment with atg/high-dose cyclophosphamide. prior cyclosporine/tacrolimus use \>12 months. prior tpo-ra therapy \>3 months. uncontrolled malignancies or conditions contraindicating atg. severe organ dysfunction (e.g., creatinine ≥177 μmol/l). investigator judgment of unsuitability.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of vsaa/saa. * age ≥65 years. * completion of all screening assessments. * must be able to swallow tablets. * signed informed consent (by patient or legal guardian if patient is incapacitated). exclusion criteria: * clonal cytogenetic abnormalities (excluding isolated -y or +8). * prior treatment with atg/high-dose cyclophosphamide. * prior cyclosporine/tacrolimus use \>12 months. * prior tpo-ra therapy \>3 months. * uncontrolled malignancies or conditions contraindicating atg. * severe organ dysfunction (e.g., creatinine ≥177 μmol/l). * investigator judgment of unsuitability.
efficacy of calmmax cream in the management of chronic uremic pruritus

Conditions: Calmmax Cream on UP in CKD Patients.

Summary: uraemic pruritus (up) remains a frequent and distressing problem in patients with advanced chronic kidney disease (ckd) and end-stage renal disease (esrd). calmmax is a new topical cream that was introduced recently by calmmax pharma, an israeli pharmaceutical company developed a topical cream based on active plant extracts for treatment of skin inflammation. we intend to conduct a prospective, double blind, placebo controlled, randomized trial that will assess the therapeutic effect of calmmax cream on up in a cohort of ckd and esrd patients.


Eligibility criteria:
inclusion criteria: 1. history of pruritus of \>8 weeks duration. 2. severity score of pruritus ≥5 as defined by vas 3. discontinuation of any medication with presumed antipruritic effects at least 1 week before the study (including calmmax cream) 4. negative pregnancy test result for all participating women of childbearing age; exclusion criteria: 1. known allergy to calmmax cream 2. any acute illness 3. liver cirrhosis 4. active dermatological disorder other than up 5. decompensated heart failure 6. inability to give informed consent 7. known poor adherence to medical recommendations

Keywords: callmax cream uremic pruritus
efficacy testing of different tourniquet pressure used for postoperative pain reduction in total knee arthroplasty

Conditions: Osteoarthritis, Knee

Summary: tourniquet use during total knee replacement (tkr) improves visibility, significantly decreases intra-operative blood loss and reduce operative time. however, tourniquet use also has a negative effect on postoperative pain, postoperative range of motion(rom), wound complication, deep vein thrombosis (dvt), pulmonary embolism (pe), thigh muscle strength, and functional recovery after tkr. therefore, the investigators conducted a three-arm prospective, randomized, controlled trial study to compare the efficacy of different tourniquet pressure used between systolic blood pressure + 75 mmhg, systolic blood pressure + 100 mmhg, and systolic blood pressure + 150 mmhg.

patients scheduled for unilateral primary tka; 150 patients were randomly assigned to receive tourniquet pressure used of systolic blood pressure + 75 mmhg, systolic blood pressure + 100 mmhg, and systolic blood pressure + 150 mmhg. all patients had spinal anesthesia, the same operative procedure, and postoperative pain protocol. a visual analogue scale (vas) for pain were recorded 24, 48 hours, and 2 weeks postoperatively. quality of bloodless visual field and calculated blood loss were evaluated perioperatively. postoperative rom, wound complication, deep vein thrombosis (dvt), pulmonary embolism (pe) were recorded at 2, 6, and 12 weeks. furthermore, knee society score (kss) also recorded at 6 weeks, 3 and 6 months. the reviewers were blinded to the treatment group.

Eligibility criteria:
inclusion criteria: * adult patients with osteoarthritis in need of a tkr exclusion criteria: * inflammatory arthritis * post-traumatic arthritis * body mass index \> 30 kg/m2 * a history of or current venous thromboembolic disease * any underlying disease of hemostasis, cirrhosis, chronic renal failure, patients on anticoagulants or strong antiplatelet drugs (e.g. warfarin, clopidogrel) * preoperative hemoglobin \<10 g/dl or a platelet count \< 140,000 /ul3 * allergy to transamine

Keywords: tourniquet total knee arthroplasty postoperative pain range of motion wound complication
filgrastim for premature ovarian insufficiency

Conditions: Premature Ovarian Failure

Summary: filgrastim is a granulocyte-colony stimulating factor (g-csf). it is an fda approved drug. very small embryonic-like stem cells (vsels) are found in the ovary. animal studies showed that these cells are able to regenerate the affected ovary. studies on mice have shown that filgrastim result in recovery of oogenesis after chemotherapy-induced gonadal failure (in 2013, 2014, and 2015).

premature ovarian insufficiency (poi) has no curative treatment until now. filgrastim is an fda approved granulocyte-colony stimulating factor (g-csf). very small embryonic-like stem cells (vsels) are found in the testis and ovary. vsels are stem cells that have noticed to survive chemotherapy induced gonadal failure. data from animal studies showed that stimulation of these stem cells result in generation of the affected gonads. studies on mice have shown a promising stimulating effect of filgrastim on recovery of spermatogenesis and oogenesis after chemotherapy-induced gonadal failure (in 2013, 2014, and 2015).

Eligibility criteria:
inclusion criteria: * women with premature ovarian insufficiency (poi): for the purpose of the research women is considered to have poi if she is aged less than 40 years and has amenorrhea of at least 4 month with fsh level above 25 iu/l (repeated twice \>4 weeks apart). exclusion criteria: * abnormal karyotype * previous pelvic or abdominal radiotherapy * previous surgical removal of the ovarian pathology * chronic disease: renal, liver, cardiac, malignancy

Keywords: premature ovarian failure filgrastim
limb remote ischemic preconditioning for heart and intestinal protection during laparoscopic colorectal surgery

Conditions: Laparoscopic Colorectal Surgery

Summary: remote ischaemic preconditioning may confer the cytoprotection in critical organs. the investigators hypothesized that limb remote ischemic preconditioning (ripc) would reduce heart and gastrointestinal function injury in middle-aged and elderly patients undergoing elective laparoscopic colorectal surgery.


Eligibility criteria:
inclusion criteria: * age \>40 years old * asa i-ii * receive elective laparoscopic colorectal surgery * written informed consent can be obtained exclusion criteria: * coagulation disorders * patients with cardiac pacemaker * patients with severe cardiac,or pulmonary,hepatic,renal disease ,or can not tolerate laparoscopic surgery * patients with peripheral vascular disease affecting the upper limbs * patients with mental,or hearing, vision disorder, who is not able to communicate with physicians * difficult airways that can not receive rapid induction
applications site reactions after injection of insulin detemir and saline in subjects with diabetes

Conditions: Diabetes Mellitus

Summary: to compare application site reactions after superficial and deep subcutaneous and intradermal injections of insulin detemir and saline in patients with diabetes - the patient serves as his own control, n=100 patients with diabetes


Eligibility criteria:
inclusion criteria: * diabetes mellitus * hba1c\<11 % * bmi: 20-35 kg/m2 * insulin detemir naive * basal insulin dose\>20e exclusion criteria: * known allergy to study drug * current steroid or antiallergic treatment * lipodystrophy * change in insulin and antihypertensive treatment \< 30 days * smokers or alcoholics
oxn pr compared to oxypr to demonstrate non-inferiority in pain & locomotor function & improvement in symptoms of constipation in oa subjects

Conditions: Chronic Osteoarthritis

Summary: the primary objectives are * to demonstrate that the treatment with oxn pr tablets is non-inferior to the treatment with oxypr with regards to analgesic efficacy and locomotor function. * to demonstrate that subjects with moderate to severe oa pain taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects taking oxycodone prolonged release tablets alone

subjects with moderate to severe pain due to osteoarthritis (oa) will be randomised to oxycodone/naloxone prolonged release (oxn pr) or oxycodone prolonged release tablets (oxypr) alone to demonstrate that the treatment with oxn pr tablets is non-inferior to the treatment with oxypr with regards to analgesic efficacy and locomotor function and to demonstrate that subjects taking oxn pr have improvement in symptoms of constipation compared to subjects taking oxypr alone.

Eligibility criteria:
inclusion criteria: * moderate to severe chronic nonmalignant oa and that require around-the-clock opioid therapy. exclusion criteria: * females who are pregnant or lactating. * subjects with evidence of significant structural abnormalities of the gastrointestinal tract. * subjects with evidence of impaired liver/kidney function upon entry into the study

Keywords: randomised double-blind double-dummy parallel-group non-inferiority pain locomotor function improvement in symptoms of constipation moderate to severe pain due to osteoarthritis (oa) oxn pr oxypr moderate to severe chronic nonmalignant oa
the kilimanjaro cervical screening project

Conditions: Uterine Cervical Neoplasms; Cervical Cancer

Summary: although highly curable, cervical cancer kills thousands of women in developing countries annually. the investigators will pilot a project to improve detection of cervical cancer in kilimanjaro, tanzania through a program that combines access to cervical screening expertise available in a large medical centre and remote use of a mobile phone camera application.


Eligibility criteria:
inclusion criteria: * female * over 18 years of age exclusion criteria: * previous removal of uterus
validation of lophius kits t-track® cmv and t-track® ebv in hemodialysis patients

Conditions: Renal Failure Chronic Requiring Dialysis

Summary: cell-mediated immunity (cmi) and in particular t cells play a critical role in the rejection of transplanted organs. thus, in transplant recipients a life-long and individualized immunosuppressive medication is required to avoid graft rejection. however, a too weak suppression of cmi causes acute and chronic graft damage leading to transplant loss, whereas a too potent suppression of cmi supports opportunistic infections and reactivation of persistent viruses. one of the biggest challenges in the field of transplantation is to provide a personalized immunosuppressive and antiviral therapy based on reliable assessment and monitoring of cmi. this could lead to a reduction of graft rejections and virus reactivations in transplant recipients. with the development of both assays t-track® cmv and t-track® ebv, lophius biosciences gmbh has implemented its novel proprietary t-activation technology for an improved assessment of the functionality of cmi in cytomegalovirus (cmv)- and/or epstein-barr virus (ebv)-seropositive individuals. in contrast to other existing systems the lophius assays open up the opportunity to characterize the functionality of cmi as an entire network. the planned clinical multicenter study aims to verify the suitability of the two assays for a reliable assessment of the functionality of cmi. hemodialysis patients have been identified as an appropriate patient cohort for investigating the clinical sensitivity of the lophius assays as these patients closely resemble kidney transplant recipients prior to an immunosuppressive therapy. the determination of the functional cmi in the course of an immunosuppressive treatment may in future enable physicians to optimize the individual immunosuppressive and antiviral therapy in transplant recipients to reduce the risk of rejection as well as virus reactivations and associated diseases.


Eligibility criteria:
inclusion criteria: * patient being hemodialysis-dependent due to end-stage kidney disease * male or female patient at least 18 years of age * written informed consent exclusion criteria: * patient requires ongoing dosing with a systemic immunosuppressive drug * patient has received immunosuppressive therapy within the last three month * patient is known to be positive for hiv or suffering from chronic hepatitis infections * patient has significant uncontrolled concomitant infections or other unstable medical conditions that could interfere with the study objectives * patient has any form of substance abuse, psychiatric disorder or condition that, in the opinion of the investigator may invalidate communication with the investigator

Keywords: cytomegalovirus epstein- barr virus cell-mediated immunity t-track® cmv t-track® ebv hemodialysis elispot